Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2023 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine

NEW YORK and VIENNA, Austria, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
December 15, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors

NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
November 30, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit

NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
November 14, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Announces Third Quarter 2022 Financial Results and Provides a Business Update

Major oncology collaboration and license agreement secured with Roche to develop HB-700 for KRAS-mutated cancers and an additional undisclosed oncology candidateInvestigational New Drug Application...
November 07, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022

NEW YORK and VIENNA, Austria, Nov. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
November 02, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference

NEW YORK and VIENNA, Austria, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
October 20, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers

Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive $25 million in upfront cash as well as potential...
September 07, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September

NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
August 11, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates

HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underwayUS Food and Drug Administration accepted HOOKIPA’s Investigational...
August 04, 2022 07:00 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022

NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...